Multinational phase 3 research evaluating aripiprazole lauroxil in patients with schizophrenia.

Alkermes continues to expect topline results from the phase 3 study in the 1st half of 2014. Related StoriesNew UCL study highlights genes associated with schizophrenia and obesityResearchers examine neuroanatomical signature of schizophrenia in different ethnic groupsVraylar capsules right now authorized by FDA to treat schizophrenia, bipolar disorder in adults Enrollment was completed following a prespecified interim analysis of sample size. The scholarly study continues to be blinded until completion.5A). 5A), which was attenuated by LY .. Statistical comparisons were carried out using a 1-way ANOVA and post-hoc Newman-Keuls tests, with p 0.05). Raw blots and gel images for panels D and B are available in Supplemental Figure 2. 5B). 5C). To determine whether PHE influences phosphorylation turnover on PKD, experiments were carried out in the presence of the calA phosphatase inhibitor and with the protein kinase A inhibitor, PKI. PKA activation of phosphodiesterases could influence phosphorylation turnover, but PKI inhibition of PKA did not change the PHE-mediated enhancement of PKD phosphorylation .